{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:05:18Z","timestamp":1790672718815,"version":"4.1.0"},"reference-count":123,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 1 (SHP-1), a non-receptor protein tyrosine phosphatase, has been reported as a negative regulator of phosphorylated signal transducer and activator of transcription 3 (STAT3) and linked to tumor development. In this present review, we will discuss the importance and function of SHP-1\/p-STAT3 signaling in nonmalignant conditions as well as malignancies, its cross-talk with other pathways, the current clinical development and the potential role of inhibitors of this pathway in anticancer therapy and clinical relevance of SHP-1\/p-STAT3 in cancers. Lastly, we will summarize and highlight work involving novel drugs\/compounds targeting SHP-1\/p-STAT3 signaling and combined strategies that were\/are discovered in our and our colleagues\u2019 laboratories.<\/jats:p>","DOI":"10.3390\/ijms18061234","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T10:26:09Z","timestamp":1496917569000},"page":"1234","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Alteration of SHP-1\/p-STAT3 Signaling: A Potential Target for Anticancer Therapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3675-2760","authenticated-orcid":false,"given":"Tzu-Ting","family":"Huang","sequence":"first","affiliation":[{"name":"Comprehensive Breast Health Center, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan"},{"name":"Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Chen","family":"Su","sequence":"additional","affiliation":[{"name":"Institute of Biopharmaceutical Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan"},{"name":"Faculty of Pharmacy, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Comprehensive Breast Health Center, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan"},{"name":"Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan"},{"name":"School of Medicine, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wai","family":"Shiau","sequence":"additional","affiliation":[{"name":"Institute of Biopharmaceutical Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuen-Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan"},{"name":"National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1039\/b606246f","article-title":"Structure, function, and regulation of STAT proteins","volume":"2","author":"Lim","year":"2006","journal-title":"Mol. Biosyst."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: From interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/13543784.2015.1020370","article-title":"Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer","volume":"24","author":"Santoni","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_4","first-page":"46","article-title":"Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma","volume":"1835","author":"Subramaniam","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00280-014-2480-2","article-title":"Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors","volume":"74","author":"Bendell","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9623","DOI":"10.1073\/pnas.1121606109","article-title":"Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts","volume":"109","author":"Zhang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.oraloncology.2015.11.022","article-title":"The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations","volume":"56","author":"Geiger","year":"2016","journal-title":"Oral Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3892\/ijo.2012.1568","article-title":"STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review)","volume":"41","author":"Wang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/acschembio.5b00945","article-title":"Strategies and Approaches of Targeting STAT3 for Cancer Treatment","volume":"11","author":"Furtek","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_11","first-page":"136","article-title":"Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors","volume":"1845","author":"Siveen","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.2174\/092986711796957284","article-title":"Small molecule inhibitors of STAT3 for cancer therapy","volume":"18","author":"Zhao","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4155\/fmc.11.22","article-title":"Signal transducer and activator of transcription 3 (STAT3): A promising target for anticancer therapy","volume":"3","author":"Masciocchi","year":"2011","journal-title":"Future Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/13543784.2016.1195807","article-title":"Novel STAT 3 inhibitors for treating gastric cancer","volume":"25","author":"Cafferkey","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1128\/MCB.18.5.2545","article-title":"Stat3 activation by Src induces specific gene regulation and is required for cell transformation","volume":"18","author":"Turkson","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/sj.onc.1205859","article-title":"Roles of activated Src and Stat3 signaling in melanoma tumor cell growth","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1742-4658.2008.06247.x","article-title":"Protein tyrosine phosphatases: Regulatory mechanisms","volume":"275","author":"Ostman","year":"2008","journal-title":"FEBS J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0014-5793(02)03842-5","article-title":"Control mechanism of JAK\/STAT signal transduction pathway","volume":"534","author":"Yamada","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jhep.2011.01.047","article-title":"Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma","volume":"55","author":"Tai","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Beldi-Ferchiou, A., Skouri, N., Ben Ali, C., Safra, I., Abdelkefi, A., Ladeb, S., Mrad, K., Ben Othman, T., and Ben Ahmed, M. (2017). Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK\/STAT3 pathway and the progression of the disease in multiple myeloma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174835"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1038\/onc.2014.445","article-title":"SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"34","author":"Fan","year":"2015","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-014-3000-0","article-title":"Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells","volume":"146","author":"Liu","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"28888","DOI":"10.1038\/srep28888","article-title":"Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1196\/annals.1378.063","article-title":"Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: Modern target but ancient solution","volume":"1091","author":"Aggarwal","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.leu.2401415","article-title":"Inhibition of constitutively activated Stat3 correlates with altered Bcl-2\/Bax expression and induction of apoptosis in mycosis fungoides tumor cells","volume":"13","author":"Nielsen","year":"1999","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/MCB.16.4.1595","article-title":"Activation and association of Stat3 with Src in v-Src-transformed cell lines","volume":"16","author":"Cao","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1128\/MCB.18.5.2553","article-title":"Stat3 activation is required for cellular transformation by v-src","volume":"18","author":"Bromberg","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc1837","article-title":"Protein-tyrosine phosphatases and cancer","volume":"6","author":"Ostman","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1128\/MCB.15.12.7050","article-title":"Differential regulation of the alpha\/beta interferon-stimulated Jak\/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1","volume":"15","author":"David","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1128\/MCB.16.12.6985","article-title":"Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1","volume":"16","author":"Jiao","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33893","DOI":"10.1074\/jbc.273.51.33893","article-title":"Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction","volume":"273","author":"Haque","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1073\/pnas.95.7.3845","article-title":"Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells","volume":"95","author":"Migone","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28199","DOI":"10.1074\/jbc.273.43.28199","article-title":"Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1","volume":"273","author":"Yang","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1074\/jbc.M210430200","article-title":"Crystal structure of human protein-tyrosine phosphatase SHP-1","volume":"278","author":"Yang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_35","first-page":"1649","article-title":"Interdependent regulation of intracellular acidification and SHP-1 in apoptosis","volume":"59","author":"Thangaraju","year":"1999","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"24448","DOI":"10.1074\/jbc.272.39.24448","article-title":"The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling","volume":"272","author":"Lopez","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jcem.87.2.8194","article-title":"Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1","volume":"87","author":"Zapata","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1084\/jem.186.9.1575","article-title":"Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes","volume":"186","author":"Delibrias","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(03)00400-1","article-title":"The function of the protein tyrosine phosphatase SHP-1 in cancer","volume":"306","author":"Wu","year":"2003","journal-title":"Gene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2003-06-2007","article-title":"SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak\/STAT pathway","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1073\/pnas.0501959102","article-title":"STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1038\/ncb0502-e131","article-title":"AP-1 as a regulator of cell life and death","volume":"4","author":"Shaulian","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1515\/bc.2011.038","article-title":"STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter","volume":"392","author":"Zugowski","year":"2011","journal-title":"Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1615\/ForumImmunDisTher.v1.i3.10","article-title":"Cross-Regulation Between Wnt and NF-kappaB Signaling Pathways","volume":"1","author":"Du","year":"2010","journal-title":"Forum Immunopathol. Dis. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-05-3460","article-title":"Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer","volume":"66","author":"Kawada","year":"2006","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2008.05.035","article-title":"Beta-Catenin\/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma","volume":"271","author":"Yan","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fragoso, M.A., Patel, A.K., Nakamura, R.E., Yi, H., Surapaneni, K., and Hackam, A.S. (2012). The Wnt\/beta-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046892"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ydbio.2005.11.011","article-title":"WNT\/beta-catenin pathway up-regulates Stat3 and converges on LIF to prevent differentiation of mouse embryonic stem cells","volume":"290","author":"Hao","year":"2006","journal-title":"Dev. Biol."},{"key":"ref_49","first-page":"269","article-title":"Wnt\/beta-catenin and LIF-Stat3 signaling pathways converge on Sp5 to promote mouse embryonic stem cell self-renewal","volume":"129","author":"Ye","year":"2016","journal-title":"J. Cell Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","article-title":"NF-\u03baB and STAT3 signaling pathways collaboratively link inflammation to cancer","volume":"4","author":"Fan","year":"2013","journal-title":"Protein Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","article-title":"Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer","volume":"21","author":"Grivennikov","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/embor.2009.243","article-title":"IKK\/NF-kappaB and STAT3 pathways: Central signalling hubs in inflammation-mediated tumour promotion and metastasis","volume":"10","author":"Bollrath","year":"2009","journal-title":"EMBO Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1002\/1521-4141(200111)31:11<3185::AID-IMMU3185>3.0.CO;2-J","article-title":"Role of host phosphotyrosine phosphatase SHP-1 in the development of murine leishmaniasis","volume":"31","author":"Forget","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1128\/IAI.00853-05","article-title":"Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production","volume":"74","author":"Forget","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/jir.1998.18.499","article-title":"Increased inducible activation of NF-\u03baB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1","volume":"18","author":"Massa","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"14274","DOI":"10.1074\/jbc.M300425200","article-title":"Negative regulation of beta-catenin signaling by tyrosine phosphatase SHP-1 in intestinal epithelial cells","volume":"278","author":"Duchesne","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00003495-200868020-00007","article-title":"Sorafenib: In hepatocellular carcinoma","volume":"68","author":"Simpson","year":"2008","journal-title":"Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1535-7163.MCT-08-0138","article-title":"Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas","volume":"7","author":"Yang","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-09-1004","article-title":"Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells","volume":"9","author":"Huang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/1535-7163.MCT-09-0947","article-title":"Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3","volume":"9","author":"Yang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_61","first-page":"408","article-title":"Sorafenib downregulates ERK\/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line","volume":"3","author":"Chai","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/CAD.0b013e32833f44fd","article-title":"Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation","volume":"22","author":"Zhao","year":"2011","journal-title":"Anti Cancer Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1158\/1078-0432.CCR-09-3389","article-title":"Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3","volume":"16","author":"Chen","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2015.11.039","article-title":"A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy","volume":"371","author":"Chao","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejmech.2012.07.023","article-title":"Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity","volume":"55","author":"Chen","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/bcr3457","article-title":"Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells","volume":"15","author":"Liu","year":"2013","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/1878-0261.12033","article-title":"Sorafenib analogue SC-60 induces apoptosis through the SHP-1\/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells","volume":"11","author":"Liu","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hep.26640","article-title":"Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma","volume":"59","author":"Tai","year":"2014","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Hu, M.H., Chen, L.J., Chen, Y.L., Tsai, M.S., Shiau, C.W., Chao, T.I., Liu, C.Y., Kao, J.H., and Chen, K.F. (2017). Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget.","DOI":"10.1016\/S0959-8049(17)30363-5"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/1535-7163.MCT-13-0595","article-title":"SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model","volume":"13","author":"Tai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.neo.2015.08.007","article-title":"Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer","volume":"17","author":"Fan","year":"2015","journal-title":"Neoplasia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.18632\/oncotarget.2191","article-title":"SHP-1 is a target of regorafenib in colorectal cancer","volume":"5","author":"Fan","year":"2014","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1158\/1078-0432.CCR-14-0725","article-title":"STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma","volume":"20","author":"Tai","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1535-7163.MCT-11-0412","article-title":"Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3","volume":"11","author":"Tai","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2014.03.017","article-title":"Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity","volume":"61","author":"Tai","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.canlet.2013.12.008","article-title":"Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases","volume":"345","author":"Lee","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2010.11.032","article-title":"Janus activated kinase 2\/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells","volume":"654","author":"Kim","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ijc.25059","article-title":"Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells","volume":"127","author":"Pandey","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Rhee, Y.H., Jeong, S.J., Lee, H.J., Lee, H.J., Koh, W., Jung, J.H., Kim, S.H., and Sung-Hoon, K. (2012). Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-28"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1111\/bph.13146","article-title":"A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia","volume":"172","author":"Jung","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/jcb.23077","article-title":"Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells","volume":"112","author":"Lee","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/1541-7786.MCR-08-0154","article-title":"Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1","volume":"7","author":"Kunnumakkara","year":"2009","journal-title":"Mol. Cancer Res. MCR"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Baek, S.H., Lee, J.H., Kim, C., Ko, J.H., Ryu, S.H., Lee, S.G., Yang, W.M., Um, J.Y., Chinnathambi, A., and Alharbi, S.A. (2017). Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase. Molecules.","DOI":"10.3390\/molecules22020276"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bph.12302","article-title":"Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3","volume":"170","author":"Subramaniam","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1476-5381.2010.01187.x","article-title":"gamma-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: Potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent","volume":"163","author":"Rajendran","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/jcp.22954","article-title":"Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1","volume":"227","author":"Rajendran","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Zhang, T., Li, S., Li, J., Yin, F., Hua, Y., Wang, Z., Lin, B., Wang, H., Zou, D., and Zhou, Z. (2016). Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition. Cell Death Dis., 7.","DOI":"10.1038\/cddis.2016.305"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/mc.22166","article-title":"Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model","volume":"54","author":"Shanmugam","year":"2015","journal-title":"Mol. Carcinogenes."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Song, S., Su, Z., Xu, H., Niu, M., Chen, X., Min, H., Zhang, B., Sun, G., Xie, S., and Wang, H. (2017). Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. Cell Death Dis., 8.","DOI":"10.1038\/s41419-018-0827-z"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1476-5381.2012.02212.x","article-title":"Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody","volume":"168","author":"Chen","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.canlet.2014.04.006","article-title":"A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3","volume":"349","author":"Huang","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1093\/carcin\/bgu210","article-title":"RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells","volume":"35","author":"Su","year":"2014","journal-title":"Carcinogenesis"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neo.2014.06.005","article-title":"SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1\/SHP-1 activation in hepatocellular carcinoma","volume":"16","author":"Su","year":"2014","journal-title":"Neoplasia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/1097-0142(197510)36:4<1250::AID-CNCR2820360410>3.0.CO;2-X","article-title":"Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication","volume":"36","author":"Olweny","year":"1975","journal-title":"Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2006.07.4955","article-title":"Doctors\u2019 and patients\u2019 preferences for participation and treatment in curative prostate cancer radiotherapy","volume":"25","author":"Stalmeier","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/jnci\/dji315","article-title":"A randomized phase III study of doxorubicin versus cisplatin\/interferon \u03b1-2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma","volume":"97","author":"Yeo","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/1097-0142(19840201)53:3<401::AID-CNCR2820530306>3.0.CO;2-L","article-title":"Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy","volume":"53","author":"Choi","year":"1984","journal-title":"Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/1097-0142(19830115)51:2<206::AID-CNCR2820510206>3.0.CO;2-P","article-title":"Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin","volume":"51","author":"Melia","year":"1983","journal-title":"Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1002\/1097-0142(197811)42:5<2149::AID-CNCR2820420510>3.0.CO;2-5","article-title":"Chemotherapy studies in primary liver cancer: A prospective randomized clinical trial","volume":"42","author":"Falkson","year":"1978","journal-title":"Cancer"},{"key":"ref_102","first-page":"429","article-title":"Combined gamma-tocotrienol and erlotinib\/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells","volume":"30","author":"Bachawal","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ijrobp.2016.01.016","article-title":"Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1\/STAT3 Signaling","volume":"95","author":"Huang","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.bcp.2011.12.035","article-title":"Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3","volume":"83","author":"Chen","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Al-Jamal, H.A., Mat Jusoh, S.A., Hassan, R., and Johan, M.F. (2015). Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1695-x"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-4598-13-7","article-title":"YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma","volume":"13","author":"Kong","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1158\/1541-7786.MCR-09-0257","article-title":"5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: Potential role in chemosensitization","volume":"8","author":"Sandur","year":"2010","journal-title":"Mol. Cancer Res. MCR"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.2015.233","article-title":"The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours","volume":"113","author":"Thomas","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pharmthera.2015.10.004","article-title":"Targeting transcription factor STAT3 for cancer prevention and therapy","volume":"162","author":"Chai","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"975350","DOI":"10.1155\/2013\/975350","article-title":"Trichosanthes kirilowii Ethanol Extract and Cucurbitacin D Inhibit Cell Growth and Induce Apoptosis through Inhibition of STAT3 Activity in Breast Cancer Cells","volume":"2013","author":"Kim","year":"2013","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.mce.2013.03.010","article-title":"Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer","volume":"382","author":"Walker","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1038\/sj.onc.1204349","article-title":"Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells","volume":"20","author":"Garcia","year":"2001","journal-title":"Oncogene"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s12026-016-8805-y","article-title":"Protein tyrosine phosphatase SHP-1: Resurgence as new drug target for human autoimmune disorders","volume":"64","author":"Sharma","year":"2016","journal-title":"Immunol. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1182\/blood-2004-08-3271","article-title":"Tyrosine phosphatase SHP-1 acts at different stages of development to regulate hematopoiesis","volume":"105","author":"Paling","year":"2005","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/ijc.24917","article-title":"Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer","volume":"126","author":"Tassidis","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000276765","article-title":"Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors","volume":"77","author":"Insabato","year":"2009","journal-title":"Oncology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2478\/raon-2014-0001","article-title":"Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma","volume":"48","author":"Peng","year":"2014","journal-title":"Radiol. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12253-008-9065-5","article-title":"Significance of SHP-1 and SHP-2 expression in human papillomavirus infected Condyloma acuminatum and cervical cancer","volume":"14","author":"Tao","year":"2008","journal-title":"Pathol. Oncol. Res. POR"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"64136","DOI":"10.18632\/oncotarget.11636","article-title":"Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer","volume":"7","author":"Fan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1042\/BST20150261","article-title":"Novel targets and interaction partners of mutant p53 Gain-Of-Function","volume":"44","author":"Aschauer","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1042\/BST20150251","article-title":"SHP-1: The next checkpoint target for cancer immunotherapy?","volume":"44","author":"Watson","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.4049\/jimmunol.1000622","article-title":"The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells","volume":"185","author":"Iype","year":"2010","journal-title":"J. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4049\/jimmunol.178.1.330","article-title":"Loss of Src homology region 2 domain-containing protein tyrosine phosphatase-1 increases CD8+ T cell-APC conjugate formation and is associated with enhanced in vivo CTL function","volume":"178","author":"Sathish","year":"2007","journal-title":"J. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/6\/1234\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:38:22Z","timestamp":1760207902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/6\/1234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":123,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["ijms18061234"],"URL":"https:\/\/doi.org\/10.3390\/ijms18061234","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}